Wilmington Savings Fund Society FSB Acquires New Position in Illumina, Inc. (NASDAQ:ILMN)

Wilmington Savings Fund Society FSB acquired a new position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 5,917 shares of the life sciences company's stock, valued at approximately $772,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Industrial Alliance Investment Management Inc. bought a new position in Illumina during the second quarter worth $34,000. TD Private Client Wealth LLC boosted its position in shares of Illumina by 58.5% during the third quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company's stock worth $50,000 after buying an additional 141 shares during the period. Massmutual Trust Co. FSB ADV increased its holdings in shares of Illumina by 65.1% during the third quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company's stock valued at $56,000 after purchasing an additional 168 shares during the period. Itau Unibanco Holding S.A. acquired a new position in Illumina during the 2nd quarter valued at about $61,000. Finally, Private Trust Co. NA raised its holdings in Illumina by 81.2% during the third quarter. Private Trust Co. NA now owns 473 shares of the life sciences company's stock worth $62,000 after purchasing an additional 212 shares in the last quarter. Hedge funds and other institutional investors own 89.42% of the company's stock.

Analyst Upgrades and Downgrades

ILMN has been the subject of several research reports. UBS Group raised their price objective on shares of Illumina from $133.00 to $145.00 and gave the company a "neutral" rating in a research report on Tuesday, November 5th. Leerink Partners raised their price target on shares of Illumina from $160.00 to $200.00 and gave the stock an "outperform" rating in a report on Thursday, October 17th. Royal Bank of Canada boosted their target price on Illumina from $252.00 to $254.00 and gave the company an "outperform" rating in a research note on Tuesday, November 5th. Barclays increased their price target on shares of Illumina from $135.00 to $145.00 and gave the stock an "equal weight" rating in a research note on Tuesday, November 5th. Finally, Canaccord Genuity Group increased their price objective on Illumina from $130.00 to $145.00 and gave the company a "hold" rating in a report on Tuesday, November 5th. Eight equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $165.95.

Illumina Price Performance

NASDAQ ILMN traded up $0.53 during trading on Monday, reaching $144.40. 1,864,291 shares of the company traded hands, compared to its average volume of 2,009,086. The stock's 50 day moving average price is $144.27 and its two-hundred day moving average price is $128.63. Illumina, Inc. has a 1-year low of $100.08 and a 1-year high of $156.66. The company has a market cap of $22.90 billion, a price-to-earnings ratio of -14.44 and a beta of 1.11. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.26. The company had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.08 billion. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The company's revenue was down 3.5% on a year-over-year basis. During the same quarter last year, the business posted $0.33 earnings per share. As a group, analysts anticipate that Illumina, Inc. will post 4.11 EPS for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.